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The Association Between IGF-1 Levels and the
Histologic Severity of Nonalcoholic Fatty Liver Disease
Laura E. Dichtel, MD, MHS1, Kathleen E. Corey, MD, MPH, MMSc2, Joseph Misdraji, MD3, Miriam A. Bredella, MD4, Melanie Schorr, MD1,
Stephanie A. Osganian5, Brian J. Young6, Joshua C. Sung6 and Karen K. Miller, MD1
OBJECTIVES: The mechanisms responsible for the development of nonalcoholic fatty liver disease (NAFLD) and progression to
nonalcoholic steatohepatitis (NASH) are incompletely understood. Growing evidence suggests that growth hormone (GH) and
insulin-like growth factor-1 (IGF-1) may have roles in the development and progression of NAFLD. We hypothesized that lower
serum IGF-1 levels would be associated with increased liver fat accumulation, inflammation, and fibrosis in a group of meticulously
phenotyped obese subjects with liver biopsies.
METHODS: A retrospective, cross-sectional study was performed at Massachusetts General Hospital, Boston, MA, USA and
St. Mary’s Hospital, Richmond, VA, USA. Liver biopsies were performed in 142 subjects during NAFLD work-up or bariatric surgery
and were graded by a single, blinded pathologist. Main outcome measures included liver histology and serum IGF-1.
RESULTS: Mean age was 52± 10 years and body mass index (BMI) was 43± 9 kg/m2. Mean serum IGF-1 was lower in subjects with
lobular inflammation (112± 47 vs. 136± 57 ng/ml, P= 0.01), hepatocyte ballooning (115± 48 vs. 135± 57 ng/ml, P= 0.05), higher
fibrosis stage (stage 2–4 vs. 0–1; 96± 40 vs. 125± 51 ng/ml, P= 0.005), and NASH (109± 45 vs. 136± 57 ng/ml, P= 0.002). All
results remained significant after controlling for age, BMI, and a diagnosis of diabetes, and all but hepatocyte ballooning (trend,
P= 0.06) remained significant after excluding individuals with cirrhosis. Steatosis was not significantly associated with mean
serum IGF-1 levels.
CONCLUSIONS: Low serum IGF-1 levels are associated with increased histologic severity of NAFLD when rigorously controlled for
age, BMI, the presence of diabetes, and after the exclusion of subjects with cirrhosis. Further investigation is warranted to
determine the differential effects of GH and IGF-1 on the development and progression of NAFLD, which could further elucidate
pathophysiology and identify therapeutic targets.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the
liver in the absence of alcohol use, is a serious complication of
obesity. Nonalcoholic steatohepatitis (NASH), the progressive
form of NAFLD, is characterized by inflammation and
hepatocellular injury, and can progress to cirrhosis in a subset
of patients.1,2 NASH-related cirrhosis is expected to be the
leading cause of liver transplant by the year 2020.3,4 There are
currently no Food and Drug Administration-approved treat-
ments for NAFLD andNASH, and weight loss remains the only
effective management strategy.5–7 However, the mechanisms
responsible for the development of NAFLD and progression to
NASH and cirrhosis are incompletely understood, and further
insight could inform the development of future therapies.8
Growth hormone (GH) is an anterior pituitary hormone that
is a key regulator of lipolysis in adipose tissue and a cytokine
with anti-inflammatory properties both systemically and at the
macrophage level. Furthermore, obesity is a well-established
state of relative GH deficiency.9–13 Insulin-like growth factor-1
(IGF-1), which is released by the liver in response to GH
stimulation, is also reduced in obesity, but not to the same
degree as GH.10,14,15 IGF-1 induces insulin sensitivity and has
been shown to have antifibrotic properties in rodent models of
liver disease, including models of NAFLD and NASH.16–19
Thus, the state of relative GH deficiency of obesity has
potential mechanistic implications in the development of
NAFLD and NASH, both with respect to the deposition of liver
fat and the progression of inflammation and fibrosis, through
reductions in both GH and IGF-1.
Consistent with this hypothesis, mice with liver-specific
mutations in theGH receptor or downstream signaling pathways
(JAK/STAT) develop hepatic steatosis.20–24 Although there are
few datawith regard to the effects of GH in humanswith NAFLD,
adults with pituitary GH deficiency have a higher incidence of
NAFLD and, in one small study, GH administration has been
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shown to reduce liver enzymes, markers of fibrosis and liver fat
in this population.25,26 GH administration has also been shown
to reduce markers of inflammation such as high-sensitivity
C-reactive protein in hypopituitary individuals with frank GH
deficiency and obese individuals with relative GH
deficiency.27–29 Moreover, IGF-1 has also been implicated in
the pathogenesis of NASH in animal models.16,30
These data raise the question of whether downregulation of
the GH/IGF-1 axis in obesity contributes to the development
and progression of NAFLD. However, data regarding the
GH/IGF-1 axis and NAFLD in obese subjects remains limited,
in particular given the challenges of studying the GH/IGF-1
axis. For example, GH is pulsatile and a single, fasting GH
measurement is not reflective of an individual’s overall GH
status. Formal stimulation testing is required for full assess-
ment of a peak-stimulated GH level, in order to provide
meaningful data, which limits the study of GH in large study
groups due to practical constraints.31 In contrast, IGF-1, which
is produced in response to GH, is easily measurable in serum
and is not pulsatile. However, it is well established that IGF-1
declines with age, body mass index (BMI), and cirrhosis—
factors that are generally associated with increasing severity
of NAFLD andNASH.12,32 Thus, careful considerationmust be
given to existing literature regarding theGH/IGF-1 axis and the
severity of NAFLD. In particular, prior studies of the relation-
ship between the histologic severity of NAFLD and IGF-1
levels have been affected by these methodological issues,
with no one study controlling for age, BMI, and the presence of
cirrhosis.33–36 Moreover, the GH/IGF-1 axis interacts in a
complex manner with glucose and insulin homeostasis.37
Thus, we sought to determine the effects of IGF-1 on the
histologic severity of NAFLD independent of age, BMI,
diagnosis of diabetes, and the presence of cirrhosis.
We hypothesized that lower serum IGF-1 levels would be
associated with increased liver fat accumulation, inflamma-
tion, and fibrosis in a group of 142 meticulously phenotyped
obese subjects with liver biopsies even after controlling for
age, BMI, and the presence of diabetes, as well as after
exclusion of subjects with cirrhosis.
METHODS
Subjects. One hundred and forty-two subjects (46% males
and 54% postmenopausal females) with liver biopsies
Table 1 Subject demographics and laboratory values
Controls
n=21
(15%)
Steatosis
n= 41
(29%)
NASH
n=80
(56%)
Overall
modela
P-value
Controls vs.
steatosis
P-value
Controls vs.
NASH
P-value
Steatosis vs.
NASH
P-value
Demographics
Age, years 50±10 55±8 50±11 NS
BMI, kg/m2 42.7±8.3 43.9±6.8 41.4±9.9 NS
Female sex, n (%) 15 (71%) 25 (61%) 36 (45%) 0.05 NS 0.03 NS
Race
White, n (%) 8 (38%) 32 (78%) 65 (81%)
African American, n (%) 13 (62%) 8 (20%) 9 (11%)
Hispanic, n (%) 0 (0%) 0 (0%) 7 (9%)
Other, n (%) 0 (0%) 1 (2%) 6 (8%)
Obesity comorbidities
Diabetes mellitus, n (%) 3 (14%) 12 (29%) 39 (49%) 0.004 NS 0.006 0.05
Diabetes medications, n (%) 2 (10%) 11 (27%) 35 (44%) 0.003 NS 0.004 NS
Hypertension, n (%) 13 (62%) 26 (63%) 51 (64%) NS NS NS NS
Hyperlipidemia, n (%) 4 (19%) 25 (61%) 50 (63%) 0.01 0.003 0.0005 NS
Obstructive sleep apnea, n (%) 5 (24%) 15 (37%) 45 (56%) 0.01 NS 0.01 0.04
Laboratory values
ALT (U/l) 33±18 45±29 71±57 o0.0001 NS o0.0001 0.0007
AST (U/l) 18±9 27±22 46±38 o0.0001 NS o0.0001 o0.0001
Alkaline phosphatase (U/l) 80±23 88±31 86±38 NS
hsCRP (mg/l) 0.7±0.6 1.1±0.9 1.0±0.8 NS
HbA1cb (%) NA 5.7±0.3 6.7±1.7 NS
Lipids
Total cholesterol (mg/dl) 190±58 173±39 171±40 NS
LDL (mg/dl) 114±50 100±36 99±36 NS
VLDL (mg/dl) 19±10 30±13 30±15 0.0023 0.0016 0.001 NS
HDL (mg/dl) 55±18 42±9 41±10 o0.0001 0.0006 o0.0001 NS
Non-HDL Cholesterol (mg/dl) 122±39 130±41 128±36 NS
Triglycerides (mg/dl) 104±52 150±83 164±109 0.0295 0.0403 0.0081 NS
ANOVA, analysis of variance; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density
lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; NA, not available; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic
steatohepatitis; NS, not significant; VLDL, very low density lipoprotein.
Values are reported as n (%) or mean± s.d.
aOverall model represents ANOVA for linear variables and Pearson’s χ2-test for categorical variables.
bHbA1c available for a subset of n= 31 subjects, 5 Steatosis, and 26 NASH.
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obtained during work-up for NAFLD or during bariatric
surgery were recruited for an Institutional Review Board-
approved (approval date: 11/10/2009) longitudinal repository
study between 2010 and 2015. Exclusionary criteria for
alcohol intake included more than two drinks per day for men
and more than one drink per day for women. Subjects with
possible drug-induced NAFLD due to steroid, methotrexate,
or tamoxifen were excluded. Overall, 34% (n=48) of subjects
in the whole cohort were on diabetes medications (Table 1),
with some subjects taking more than one such medication.
Eighty-six percent (n=38) were on metformin, 44% (n=21)
on insulin, 38% (n=18) on sulfonylureas, 8% (n=4) on
glucagon-like peptide-1 agonists, and 2% (n= 1) was on both
a dipeptidyl peptidase-4 inhibitor and thiazolidinedione. Six
subjects with a diagnosis of diabetes were not taking a
diabetes-related medication. Baseline characteristics for
different subsets of this cohort have been reported
elsewhere.38–42 IGF-1 results have not been reported
elsewhere for any of the cohort. Presence of diabetes,
diabetes medication use, hypertension, and sleep apnea
were self-reported by subjects and confirmed by physician
chart review.
Liver biopsy analysis. Biopsies were reviewed by a single,
blinded hepatopathologist (JM) and scored for steatosis
grade (0=o5%, 1=5–33%, 2= 33–66%, and 3466%),
lobular inflammation per 200× (0=no foci, 1 corresponding
too2 foci, 2 corresponding to 2–4 foci, and 3 corresponding
to 44 foci) and hepatocyte ballooning (0=no ballooning,
1= few, and 2=many) as per Kleiner et al.43 NAFLD activity
score was then assigned from 0 to 8 as a sum of the steatosis
grade, lobular inflammation, and hepatocyte ballooning
values.43 Fibrosis stage was assessed according to the modi-
fied Brunt stage (0–4), with four representing cirrhosis.43
Subject classification. Subjects were classified into sub-
groups for further analysis based on histologic assessment
(Table 1). Controls (n=21/142, 15%) were defined as
steatosis grade of 0 with no lobular inflammation, steatosis
or fibrosis. Steatosis (n=41/142, 29%) was defined by grade
1 or higher steatosis not meeting the criteria for NASH. NASH
(n=80/142, 56%) was defined as grade ≥ 1 in steatosis, ≥ 1
in lobular inflammation, and ≥ 1 in hepatocyte ballooning as
per the American Association for the Study of Liver
Disease.44 Cirrhosis (n=8/142, 6%) was defined as stage
4/4 fibrosis.
Insulin-like growth factor-1. Serum IGF-1 was measured in
batch for all subjects using an Immulite 2000 Immunoassay
System (Siemens Medical Systems, Erlangen, Germany), a
solid-phase enzyme-labeled chemiluminescent immuno-
metric assay with a coefficient of variation below 5%.
Statistical analysis. JMP Pro Statistical Database Software
(version 11.0.0; SAS Institute, Cary, NC) was used for
statistical analyses. Results are expressed as mean± s.d.
unless otherwise noted. Variables were log-transformed and
means compared with Fisher’s least significance testing for
three-way comparisons,45 t-test for two-way comparisons for
continuous variables, and the χ2-test for categorical variables.
Multivariable analysis was performed using linear or nominal
logistic regression as appropriate. All multivariable analyses
Table 2 Liver histology characteristics
Controls (n= 21) Steatosis (n= 41) NASH (n=80)
Steatosis grade (0–3)
Grade 0, n (%) 21 (100%)
Grade 1, n (%) 28 (68%) 24 (30%)
Grade 2, n (%) 11 (27%) 31 (39%)
Grade 3, n (%) 2 (5%) 25 (31%)
Lobular inflammation score (0–2)
Grade 0, n (%) 21 (100%) 31 (76%)
Grade 1, n (%) 8 (20%) 60 (75%)
Grade 2, n (%) 2 (5%) 20 (25%)
Ballooning grade (0–2)
Grade 0, n (%) 21 (100%) 16 (39%)
Grade 1, n (%) 20 (49%) 38 (48%)
Grade 2, n (%) 5 (12%) 42 (53%)
Fibrosis stage (0–4)
Stage 0, n (%) 21 (100%) 23 (56%) 18 (23%)
Stage 1, n (%) 18 (44%) 38 (48%)
Stage 2, n (%) 12 (15%)
Stage 3, n (%) 4 (5%)
Stage 4, n (%) 8 (10%)
NAS
0–2 n (%) 21 (100%) 27 (66%)
2–4 n (%) 13 (32%) 30 (38%)
5–8 n (%) 1 (2%) 50 (63%)
NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis.
Liver histology characteristics by group reported as n (%).
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were controlled for both age and BMI. Sensitivity analyses
were performed with regard to gender and the presence of
cirrhosis where noted.
RESULTS
Clinical characteristics. Clinical characteristics are reported
in Table 1. Overall mean subject age was 52± 10 years and
mean BMI was 43±9 kg/m2 with a cohort that was 53%
female (67/142). There was no difference in age, BMI, or sex
between the control, NAFLD, or NASH groups. The NASH
group had a significantly higher rate of diabetes mellitus
and obstructive sleep apnea than the control and NAFLD
groups. The NASH and NAFLD groups had similar rates of
hyperlipidemia that were both higher than the rate in controls.
Hypertension was equally prevalent across all three groups.
Liver histology characteristics of each group are reported
in Table 2.
IGF-1 and histologic assessment. The presence of lobular
inflammation was associated with lower mean serum IGF-1
(112± 47 vs. 136± 57 ng/ml, P= 0.01; Figure 1a). Hepato-
cyte ballooning was associated with lower mean serum IGF-1
levels (115±48 vs. 135± 57 ng/ml, P= 0.05; Figure 1b).
Subjects with NASH had lower mean serum IGF-1 levels than
those without NASH (controls or steatosis alone; 109±45 vs.
136±57 ng/ml, P= 0.002; Figure 1c). In addition, mean
serum IGF-1 was lower in subjects with higher fibrosis stage
(stage 2–4 vs. 0–1; 96±40 vs. 125± 51 ng/ml, P=0.005;
Figure 1d). Steatosis by any measure was not significantly
associated with mean serum IGF-1 levels (steatosis absent
133±56 vs. steatosis present 118±54 ng/ml, P=NS;
Figure 1e).
As expected, based on known physiology, the presence of
cirrhosis was associated with lower mean serum IGF-1 levels
(90±38 vs. 122±51 ng/ml, Po0.05; Figure 1f). Thus, a
sensitivity analysis was performed for each of the remaining
variables excluding individuals with cirrhosis. Lobular inflam-
mation, the presence of NASH, and higher fibrosis stage
continued to be significantly associated and hepatocyte
ballooning a trend (P=0.06) with lower mean serum IGF-1
when subjects with cirrhosis were excluded. To assess
whether lower levels of fibrosis could be contributing to a
decrease in IGF-1 levels, we performed a subset analysis of all
individuals with minimal fibrosis (F0–1, n= 117). Despite a
significant loss in power, individuals with NASH still had a
significantly lower mean serum IGF-1 than those without
NASH (115±8 vs. 137± 8 ng/ml, P= 0.02).
Models controlling for diabetes and glucose homeosta-
sis. When controlled for the presence or absence of
diabetes in addition to age and BMI, lower mean serum
IGF-1 remained significantly associated with fibrosis
(P=0.003), lobular inflammation (P=0.002), hepatocyte
ballooning (P= 0.02), and NASH (P=0.0003) but not
steatosis. Hemoglobin A1c (HbA1c) measurements were
available in a subset of individuals without cirrhosis from the
cohort (n= 27, 19%), including 13 women and 14 men. Five
individuals in this subgroup had NAFLD and 22 had NASH.
Mean age was 49± 11 years, mean BMI was 34±7 kg/m2,
and mean HbA1c was 6.5±1.6% (range 4.8–11.5%). When
controlled for age and BMI in this subgroup, lower mean
serum IGF-1 was associated with NASH (P=0.01) and
hepatocyte ballooning (P=0.03), but not lobular inflamma-
tion, fibrosis, or steatosis. When controlled for age, BMI, and
HbA1c, lower mean serum IGF-1 remained significantly
associated with the presence of NASH (P= 0.002) but the
relationship between mean serum IGF-1 and hepatocyte
ballooning was lost (P= 0.9). Of note, in this small subset,
higher HbA1c was significantly associated with the presence
of NASH (P= 0.001) and by trend with steatosis (P= 0.06),
lobular inflammation (P=0.06), and fibrosis (P=0.07).
Finally, we repeated the primary analysis controlling for the
use of any medication used to treat diabetes mellitus rather
than diagnosis of diabetes itself. All findings in Figure 1
remained unchanged and the use of medications for the
treatment of diabetes mellitus did not have an impact on
mean serum IGF-1 levels in any model. This was true even
after excluding the n=5 subjects on a glucagon-like peptide-
1 agonist or thiazolidinedione.
Models controlling for race. The effect of Caucasian and
African American groups was examined with respect to this
analysis. There was no difference in mean serum IGF-1
levels between the Caucasian and African American groups
(128±53 vs. 125±59 ng/ml), and in addition there was no
effect of race on mean serum IGF-1 levels (model was also
controlled for BMI and age). The central analysis investigat-
ing the relationship between mean serum IGF-1 levels and
histology (Figure 1) was unchanged when controlling for race,
with significantly lower mean serum IGF-1 levels in indivi-
duals with lobular inflammation, hepatocyte ballooning,
NASH, increasing fibrosis severity, and cirrhosis. In addition,
race was not significant in these models (P40.1 in all
models). The only difference noted was that controlling for
race strengthened the difference between mean serum IGF-1
levels in the steatosis group and controls (133± 5 vs.
110±11 ng/ml, respectively, P= 0.09), which was previously
not significant.
DISCUSSION
In this study, we demonstrate that markers of inflammation,
hepatocyte ballooning, and fibrosis, but not steatosis, are
associated with low serum IGF-1 levels in meticulously
phenotyped patients with biopsy-proven NAFLD, even when
controlling for age and BMI, and after excluding individuals
with cirrhosis. In addition, our data show that serum IGF-1
remained a significant predictor of NASH even after addition-
ally controlling for a diagnosis of diabetes or HbA1c,
demonstrating that the GH/IGF-1 axis may have a role in the
development and progression of NAFLD and NASH, inde-
pendent of its association with insulin resistance and glucose
homeostasis. These data thus implicate the GH/IGF-1 axis in
the development and progression of NAFLD.
Thiswork builds on the existing literature that suggests a link
between GH/IGF-1 axis deficiency and NAFLD, while employ-
ing a rigorous approach to histological assessment, hormonal
evaluation, and adjustment for potential confounders that has
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Figure 1 Reported as mean serum insulin-like growth factor-I (IGF-1) in ng/ml± s.e.m. *Po0.05 as specified below. (a) Mean serum IGF-1 was significantly lower in
subjects with the presence (“present”) vs. the absence (“absent”) of lobular inflammation (P= 0.01). (b) Subjects with hepatocyte ballooning had significantly lower mean serum
IGF-1 levels than those without (Po0.05). (c) Subjects with nonalcoholic steatohepatitis (NASH) (“present”) had significantly lower mean serum IGF-1 when compared with those
without NASH (“absent”)(P= 0.002). (d) Subjects with more severe fibrosis (Stages 2–4) had significantly lower mean serum IGF-1 levels than those with less severe fibrosis
(Stages 0–1) (Po0.005). All results remained significant when excluding individuals with cirrhosis with the exception of hepatocyte ballooning, which remained a trend at
P= 0.06. (e) Mean serum IGF-1 level was not significantly different in subjects with steatosis (“present”) vs. controls without steatosis (“absent”) (P=NS), which was unchanged
after excluding those with cirrhosis. (f) Mean serum IGF-1 was lower in subjects with cirrhosis (“present”) vs. those without cirrhosis (“absent”) (Po0.05).
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been absent from many prior studies. As obesity is a well-
defined state of relative GH deficiency, further study of the GH/
IGF-1 axis dysfunction in the development and progression of
NAFLD and NASH is of critical importance.
Multiple mouse models have implicated the GH/IGF-1 axis
in the development of NAFLD.20,21,23,24,46 Liver-specific GH
receptor knockout mice develop significant steatosis com-
pared with controls.22,24 In addition, liver-specific knockouts of
GH receptor signaling pathway components, including JAK2
and STAT, cause significant hepatic steatosis in mice.20,21
Moreover, low levels of GH in mice with fatty liver have been
associated with epidermal growth factor receptor downregula-
tion, a pathway that is critical to liver regeneration. GH
administration in these mice normalized hepatocyte prolifera-
tion and epidermal growth factor receptor activation after
partial hepatectomy, suggesting that GH-dependent activation
of epidermal growth factor receptor is critical to hepatic
regeneration.46
It is difficult to tease out the direct vs. indirect effects of GH
on NAFLD, as GH has a complex relationship with insulin
resistance, which itself is a factor that has been implicated in
the development and progression of NAFLD. Both GH
deficiency and GH excess are both associated with insulin
resistance and worsening glucose homeostasis. For example,
Qin et al.47 demonstrated that GH administration worsened
insulin resistance in normally fed control rats but improved
insulin resistance in rats with NAFLD and associated meta-
bolic comorbidities from a high-fat diet. Interestingly, List
et al.48 revealed even more complexity in this relationship,
demonstrating improvement in glucose tolerance but no
change in insulin levels in response to GH administration in
a high-fat fed mousemodel. Thus, the reduction in liver fat with
GH administration in this cohort was not mediated by a change
in absolute insulin levels but possibly a reduction in insulin
resistance.48 Finally, Cordoba-Chacon et al.24 implicated an
increase in de novo lipogenesis in the deposition of liver fat in
adult GH receptor knockout mice. Interestingly, the typical
pathway by which insulin regulates de novo lipogenesis (via
SREBP-1) was not upregulated in this model, suggesting the
effect of GH on de novo lipogenesis is not mediated via
insulin.24 Thus, the relationship between GH and insulin
resistance, as well as the exact mechanisms of the impact of
GH on NAFLD require further study.
IGF-1, which is produced in the liver in response to GH, is an
integral part of the GH/IGF-1 axis and of growing interest with
respect to NAFLD andNASH.30 Although the IGF-1 receptor is
not widely expressed in normal hepatocytes,49,50 it is
expressed in other types of hepatic cells. For example, hepatic
stellate cells, which are involved in liver regeneration, have
been shown to express the IGF-1 receptor, and overexpres-
sion of this receptor has been shown to enhance hepatic
regeneration in mouse models.17 There may also be direct
effects of IGF-1 on hepatocytes in the presence of liver
disease, as studies have demonstrated increased IGF-1
receptor expression in human hepatoma cells in the regen-
erative state.49 Human hepatic tissue from patients with
cirrhosis and chronic hepatitis C confirmed this finding if
IGF-1 receptor upregulation.50 Moreover, IGF-1 administration
has been shown to improve fibrosis in a mouse model of
cirrhosis.18,19,51 In addition, IGF-1 has direct insulin-
sensitizing effects,52 which could have a role in the ameliora-
tion of the NAFLD/NASH phenotype in these models.
In fact, both GH and IGF-1 have been implicated concur-
rently in the pathogenesis of NAFLD and progression to NASH
in animal models. As an example, spontaneous dwarf rats
have been studied as a murine model of NASH, as they
produce no GH and low levels of IGF-1 compared with normal
rats, and develop hepatic steatosis, elevated liver enzymes,
and fibrosis by 20 weeks of age.16 In separate groups, both
GH replacement and IGF-1 replacement normalized IGF-1
levels, reduced hepatic triglyceride content, decreased
measures of oxidative stress, and ameliorated hepatocyte
mitochondrial abnormalities. Interestingly, IGF-1 replacement
alone also led to a significant reduction in liver fibrosis.16 In
short, there is growing evidence that both GH and IGF-1 have
a role in the development of NAFLD and progression to NASH.
Human data also support the role of the GH/IGF-1 axis in
NAFLD and NASH. Studies of hypopituitary patients with frank
GH deficiency have a higher rate of NAFLD compared with
age- and BMI-matched controls (77 vs. 12%, respectively,
Po0.001). In addition, administration of physiologic GH
replacement decreased alanine transaminase, aspartate
transaminase, high-sensitivity C-reactive protein, andmarkers
of fibrosis in a group of hypopituitary individuals with GH
deficiency, more than half of whom had NAFLD. Histologic
steatosis and fibrosis scores improved in a small subset of
patients (n=5) with pre- and post-GH treatment biopsies.25
Although this is a complex model of NAFLD and NASH, as
hypopituitary patients often have other hormonal deficiencies
that require adrenal, gonadal, and thyroid hormone replace-
ment, these data suggest a possible effect of the GH/IGF-1
axis on NAFLD.
Obesity is a well-established state of relative GH deficiency
in humans, with multiple studies showing a decrease in
measures of GH with increasing BMI.9–13 However, the
GH/IGF-1 axis has not been well characterized in biopsy-
proven NAFLD. Existing studies of the GH/IGF-1 axis in
patients with NAFLD have led to exciting data that potentially
implicate the GH/IGF-1 axis in NAFLD, but they have also
been confounded by methodological difficulties.33–36,53–57 GH
is most often assessed by one fasting measurement rather
than a gold-standard GH stimulation test or frequent
sampling.34,54,56 Moreover, most studies rely on ultrasound
for the diagnosis of NAFLD,53–59 including the most rigorous
one showing lower mean peak stimulated GH levels in 65
subjects with NALFD compared with 55 controls of similar
mean age and BMI.53 These data are very suggestive for an
effect of relative GH deficiency on development of steatosis.
However, ultrasound cannot quantify intrahepatic lipid content
or assess for inflammation and fibrosis, and, in addition, has
poor sensitivity for the detection of NAFLD, in particular with
increasing BMI and at more mild levels of steatosis.60,61
A few studies before ours have also explored the relation-
ship between histologic severity of NAFLD and IGF-1 levels,
which provide an integrated measure of GH but additionally
reflect the independent hormonal actions of IGF-1 throughout
the body. However, IGF-1 decreases significantly with both
increasing BMI and age,14,62 and no studies are controlled for
both of these variables.33–36 In addition, end-stage liver
disease has been shown to blunt the production of IGF-1 in
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response toGH,32 yet patientswith cirrhosis are often included
in analyses of IGF-1 levels.33 Thus, it is imperative to control
for these factors that are concurrently associated with
decreased activation of the GH/IGF-1 axis and increased
severity of NAFLD when investigating this relationship.
In short, although prior histologic studies of NAFLD overall
suggest a role of the GH/IGF-1 axis in this disease process,
rigorously controlled studies are still lacking. Our study
confirmed the association between low IGF-1 levels and
lobular inflammation, hepatocyte ballooning, fibrosis, and
NASH, while controlling for age and BMI. We additionally
controlled for race and performed a sensitivity analysis
excluding thosewith cirrhosis with similar results. Interestingly,
our data suggest that the GH/IGF-1 axis could potentially be
involved in the progression of inflammation, hepatocyte
ballooning, fibrosis, and NASH. These findings could reflect
a combination of the anti-inflammatory properties of GH and
anti-fibrotic properties of IGF-1. Given that it is poorly
understood why some individuals with simple steatosis
progress to NASH while others do not, our data implicate the
GH/IGF-1 axis in this process and suggest that low-dose GH
may be a potential treatment for patients with NASH.
In addition, the GH/IGF-1 axis is closely interlaced with
insulin resistance and glucose homeostasis. This relationship
is complex, given that both GH deficiency and GH excess can
lead to insulin resistance, whereas IGF-1 generally acts as an
insulin sensitizer.37 Given this complex relationship and that
insulin resistance has been implicated in the development and
progression of NAFLD and NASH, we sought to identify
independent effects of the GH/IGF-1 axis on these histologic
endpoints. Interestingly, our findings were independent of a
diagnosis of diabetes mellitus, and in the small subset of
patients for which HbA1c data were available, we found that
IGF-1 was independently associated with NASH, even after
controlling for HbA1c. Furthermore, a significant proportion of
our cohort had diabetes mellitus and were receiving at least
one diabetesmellitus-relatedmedication. Althoughmetformin,
sulfonylureas, and insulin have not been found to prevent or
reverse NAFLD,63 there are some limited data that glucagon-
like peptide-1 agonists64 and thiazolidinediones63 may
improve NAFLD. However, all results were unchanged when
excluding subjects (n=5) who were on a glucagon-like
peptide-1 agonist or thiazolidinedione, suggesting that
taking medications for diabetes mellitus did not have an
impact on the relationship between IGF-1 and NAFLD
histology in this cohort.
This study is limited by a cross-sectional design. In addition,
we did not have fasting glucose and insulin measurements on
this cohort and only had HbA1c on a subgroup, which limited
our overall evaluation of the interaction between the GH/IGF-1
axis, glucose homeostasis, and NAFLD. In addition, we were
not able to perform GH stimulation testing and measurement
of random levels of this pulsatile hormone is not useful.
Although low IGF-1 is a reflection of low GH levels, IGF-1 is
relatively preserved in obesity compared with GH. Thus, it is
possible that GH levels would show an even stronger
association with features of NASH, including inflammation,
hepatocyte ballooning, and fibrosis.
This work suggests that dysregulation of the GH/IGF-1 axis
in obesity may contribute to the progression from NAFLD to
NASH. Further investigation is warranted to determine the
differential effects of the GH/IGF-1 axis on the development
and progression of NAFLD. Future research in this area could
clarify the impact of the relative GH deficiency of obesity on the
development of NAFLD and progression to NASH, with the
potential for the identification of new therapeutic targets.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ The pathophysiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH) is
incompletely understood.
✓ Growth hormone (GH) is released from the pituitary gland
and acts on the liver to produce insulin like growth factor-1
(IGF-1).
✓ GH induces lipolysis and has anti-inflammatory effects,
whereas IGF-1 is an insulin sensitizer with possible
antifibrotic effects.
✓ Obesity is a state of relative GH/IGF-1 axis deficiency.
✓ Prior studies have suggested an association between low
IGF-1 levels and worsening histologic severity of NAFLD;
however, analyses have not controlled for age, body mass
index (BMI), and the presence of cirrhosis, all three of which
are associated with both NAFLD and low IGF-1.
WHAT IS NEW HERE
✓ Low serum IGF-1 levels predict higher severity of hepatic
inflammation and fibrosis, but not steatosis, in patients with
NAFLD when controlled for age and BMI, and after
excluding individuals with cirrhosis.
✓ This relationship remained significant when controlling for a
diagnosis of diabetes, suggesting that GH/IGF-1 axis
deficiency is associated with severity of NAFLD
independent of changes in glucose homeostasis.
✓ Further investigation is warranted to determine whether
relative GH/IGF-1 axis deficiency may contribute to the
etiopathology of NAFLD and NASH.
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